Haematology Oncology Outpatient Department, St George's Hospital, Blackshaw Road, London SW170QT, UK.
Eur J Oncol Nurs. 2010 Jul;14(3):205-10. doi: 10.1016/j.ejon.2009.12.003. Epub 2010 Feb 2.
This paper reports a review of the literature with a specific focus on osteonecrosis of the jaw. Bisphosphonate drugs are commonly used in the treatment of bone disease secondary to myeloma and solid tumours, such as breast and prostate cancer. In the past few years, an uncommon but distressing condition known as osteonecrosis of the jaw (ONJ) has been detected in patients who are having bisphosphonate treatment, particularly the intravenous (IV) preparations. Osteonecrosis of the jaw results from bone exposure in the oral cavity with subsequent death of bone tissue (necrosis).
The review searched key databases including Medline, British Nursing Index, Cochrane, and meeting abstracts to ascertain the extent of literature in this field.
Fourty-two articles were reviewed which described the clinical manifestations of ONJ, the reported incidence and clinical cases.
The results indicate there is an emerging body of evidence in this field and nurses delivering bisphosphonates need to familiarise themselves with the current guidance to ensure risks are minimised for patients.
本文对文献进行了综述，重点关注颌骨坏死。双膦酸盐类药物常用于治疗骨髓瘤和实体瘤（如乳腺癌和前列腺癌）引起的骨病。在过去几年中，人们发现一种罕见但令人痛苦的疾病，即颌骨坏死（ONJ），这种疾病发生在接受双膦酸盐治疗的患者中，特别是静脉内（IV）制剂。颌骨坏死是由于口腔内的骨暴露，随后骨组织死亡（坏死）所致。
本综述检索了包括 Medline、英国护理索引、Cochrane 和会议摘要在内的主要数据库，以确定该领域文献的范围。
综述了 42 篇描述 ONJ 的临床表现、报告的发病率和临床病例的文章。
结果表明，该领域正在出现越来越多的证据，提供双膦酸盐的护士需要熟悉当前的指导，以确保将患者的风险降到最低。
Zotero 插件